Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Bio… Read more
Sernova Biotherapeutics Inc (PSH0) - Total Assets
Latest total assets as of October 2025: €764.23K EUR
Based on the latest financial reports, Sernova Biotherapeutics Inc (PSH0) holds total assets worth €764.23K EUR as of October 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sernova Biotherapeutics Inc - Total Assets Trend (2022–2025)
This chart illustrates how Sernova Biotherapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sernova Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (October 2025)
Sernova Biotherapeutics Inc's total assets of €764.23K consist of 68.4% current assets and 31.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.7% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Sernova Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sernova Biotherapeutics Inc's current assets represent 68.4% of total assets in 2025, a decrease from 97.3% in 2022.
- Cash Position: Cash and equivalents constituted 34.7% of total assets in 2025, up from 7.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sernova Biotherapeutics Inc Competitors by Total Assets
Key competitors of Sernova Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sernova Biotherapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sernova Biotherapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sernova Biotherapeutics Inc is currently not profitable relative to its asset base.
Sernova Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.32 | 0.32 |
| Quick Ratio | 0.02 | 0.32 | 0.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-24.27 Million | € -13.55 Million | € -13.55 Million |
Sernova Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sernova Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.36 |
| Latest Market Cap to Assets Ratio | 43.40 |
| Asset Growth Rate (YoY) | -89.8% |
| Total Assets | €764.23K |
| Market Capitalization | $33.17 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sernova Biotherapeutics Inc's assets at a significant premium ( 43.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Sernova Biotherapeutics Inc's assets decreased by 89.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sernova Biotherapeutics Inc (2022–2025)
The table below shows the annual total assets of Sernova Biotherapeutics Inc from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | €764.23K | -89.85% |
| 2024-10-31 | €7.53 Million | -65.95% |
| 2023-10-31 | €22.11 Million | -57.88% |
| 2022-10-31 | €52.48 Million | -- |